Pfizer's Paxlovid pill uses a combination of two antiviral drugs to prevent the virus that causes COVID-19 from replicating once it has infected a patient.

Pfizer began a rolling submission with Health Canada in December for Paxlovid, which it said is designed to block a key enzyme needed for the COVID-19 virus to multiply.